✦ LIBER ✦

Treatment of Type 1 Diabetes with Anti-CD3 Monoclonal Antibody

✍ Scribed by Mariela Glandt; William Hagopian; Kevan C. Herold

Book ID: 111568902
Publisher: Springer
Year: 2003
Tongue: English
Weight: 101 KB
Volume: 4
Category: Article
ISSN: 1389-9155
DOI: 10.1023/a:1027354129493

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of type 1 diabetes with anti-C

Treatment of type 1 diabetes with anti-CD3 monoclonal antibody

✍ Kaven C. Herold; Lesley Taylor 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 113 KB

Anti-CD3 Monoclonal Antibody in New-Onse

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

✍ Herold, Kevan C.; Hagopian, William; Auger, Julie A.; Poumian-Ruiz, Ena; Taylor, 📂 Article 📅 2002 🏛 Massachusetts Medical Society 🌐 English ⚖ 110 KB

Anti-CD3 monoclonal antibody treatment i

Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis

✍ J. Smith-Palmer; B. H. Curtis; K. S. Boye; G. Goodall; S. R. Pillemer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Use of Anti-CD3 Monoclonal Antibody to I

Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes

✍ BRYGIDA C. BISIKIRSKA; KEVAN C. HEROLD 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 799 KB

Treatment of posttransplantation diabete

Treatment of posttransplantation diabetes mellitus with anti-CD20 monoclonal antibodies

✍ K. Vandenbosch; M.A. Champagne; M. Gonthier; A. Moghrabi; M.-F. Vachon; M. Duval 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Anti-CD3 mAbs for treatment of type 1 di

Anti-CD3 mAbs for treatment of type 1 diabetes

✍ Adam Kaufman; Kevan C. Herold 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract The use of anti‐CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti‐human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non‐FcR binding antibodies: Te